** Shares of drug developer Relmada Therapeutics rise 4.9% to 48 cents
** Co says it has commenced a process to explore strategic alternatives after discontinuing two late-stage studies planned for the development of its depression drug
** Co plans to consider a wide range of options including sale of company assets, a sale of the company, a merger or a reverse merger; adds it has not set a timetable for completion of the evaluation process
** Says co is in the process of engaging a financial advisor to assist in the strategic review process
** The stock fell more than 70% last week after the company said its depression drug, esmethadone, was "unlikely" to meet the main goal of a late-stage trial
** Including session moves, stock down 88.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.